UCSD Medical CenterWIKIMEDIA, COOLCAESARThe University of California, San Diego, (UCSD) has named a new head of its Alzheimer’s Disease Cooperative Study (ADCS), even as its court battle with the University of Southern California (USC)—over the departure of the former head of the project—rages on. UCSD tapped Howard Feldman, a neurologist from the University of British Columbia in Vancouver, to lead the ADCS. “Dr. Feldman is an extraordinarily accomplished physician and scientist, a thought leader in Alzheimer’s disease clinical research,” Pradeep Khosla, chancellor of UCSD, said in a January 14 statement. “His research—and the many trials he has led—has been vastly influential in the field. His leadership will take ADCS to new levels, and further elevate UC San Diego’s standing as a pioneering institution in Alzheimer’s research and treatment.”
Feldman, whose appointment must first be approved by the National Institute on Aging (a major funder of the project), will take over the reins from Paul Aisen, who led the ADCS until his abrupt departure from UCSD last June to take a position at USC. All sorts of legal ugliness ensued, with UCSD suing USC, alleging that Aisen sought to move data and personnel associated with the ADCS to his new institution. Aisen later countersued, claiming that UCSD tried to intimidate some of his UCSD colleagues and dissuade them from joining him in USC. In July, a San Diego Superior Court judge sided with UCSD, requiring USC to cede control of the ADCS.
According to Xconomy, the matter has been taken up by federal court, ...
